Objective: In this observational study 80 biopsy-proven CrGN were included. Patients’ data regarding demographic profile, clinical parameters, treatments and outcomes were collected and analyzed.  Methods: 5.7% biopsies were having CrGN. Mean age in our study population was 40.86 ± 16.5 years. Type II CrGN was most common type followed by type III and type I CrGN.  Female predominance was observed in type I and type II CrGN, whereas type III was more predominant in males (table 1).  The highest percentage of glomeruli with crescents was seen in type I (87 ± 15.2%, p=0.04) followed by type III (76.4 ± 21.4%) and type II (70.2 ± 18.1%).Hemodialysis was needed in more than half of the cases at the time of presentation and was significantly more common in type I (72.7%) and type II (57.6%) CrGN (p=0.0034). Nearly half of the cases (53.7%) received combination of steroid and cyclophosphamide, most commonly in type III (66.7%) followed by type I (45.5%) CrGN (p=0.0381). At the last follow-up, mean serum creatinine and eGFR were 3.86 ± 3.2 mg/dl and 25.8 ± 11.41 mL/min/1.73 m 2 respectively and was significantly lower in type I CrGN(6.7 ± 5.1 mg/dl and 11.6 ± 4.8 mL/min/1.73 m 2 respectively). The overall 5-y renal survival rate was 55% and was highest in type II (69.4%) followed by type III (48.5%) and lowest in type I (27.3%) CrGN(p=0.0299).  Results: Type II CrGN was the most common type of CrGN followed by type III CrGN. Among type II CrGN, Lupus followed by IgA nephropathy were predominant causes.5 year renal survival was significantly less in type I compared to type II and type III CrGN. Conclusions: Objective: The aim of this study is to identify the etiology and clinicopatholical features and outcomes of Crescentic glomerulonephritis (CrGN). Methods: In this observational study 80 biopsy-proven CrGN were included. Patients’ data regarding demographic profile, clinical parameters, treatments and outcomes were collected and analyzed.  Results: 5.7% biopsies were having CrGN. Mean age in our study population was 40.86 ± 16.5 years. Type II CrGN was most common type followed by type III and type I CrGN.  Female predominance was observed in type I and type II CrGN, whereas type III was more predominant in males (table 1).  The highest percentage of glomeruli with crescents was seen in type I (87 ± 15.2%, p=0.04) followed by type III (76.4 ± 21.4%) and type II (70.2 ± 18.1%).Hemodialysis was needed in more than half of the cases at the time of presentation and was significantly more common in type I (72.7%) and type II (57.6%) CrGN (p=0.0034). Nearly half of the cases (53.7%) received combination of steroid and cyclophosphamide, most commonly in type III (66.7%) followed by type I (45.5%) CrGN (p=0.0381). At the last follow-up, mean serum creatinine and eGFR were 3.86 ± 3.2 mg/dl and 25.8 ± 11.41 mL/min/1.73 m 2 respectively and was significantly lower in type I CrGN(6.7 ± 5.1 mg/dl and 11.6 ± 4.8 mL/min/1.73 m 2 respectively). The overall 5-y renal survival rate was 55% and was highest in type II (69.4%) followed by type III (48.5%) and lowest in type I (27.3%) CrGN(p=0.0299).  Conclusions: Type II CrGN was the most common type of CrGN followed by type III CrGN. Among type II CrGN, Lupus followed by IgA nephropathy were predominant causes.5 year renal survival was significantly less in type I compared to type II and type III CrGN.